Angiotensin II and Senescence-Driven AAA: Novel Mechanistic Intersections

Introduction

Abdominal aortic aneurysm (AAA) remains a clinically challenging vascular disease, marked by insidious progression and catastrophic risk of rupture. Recent advances have underscored the importance of molecular mechanisms, such as cellular senescence, in AAA development and progression. Parallel to these discoveries, Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), a potent vasopressor and GPCR agonist, has emerged as a foundational tool in preclinical AAA models due to its ability to induce vascular remodeling, vascular smooth muscle cell hypertrophy, and pro-inflammatory responses. While prior literature has emphasized Angiotensin II-mediated vascular injury and smooth muscle cell (VSMC) hypertrophy, the intersection between Angiotensin II signaling and cellular senescence in AAA remains underexplored. This article provides a comprehensive synthesis of emerging evidence linking Angiotensin II-induced signaling pathways with senescence-driven vascular pathology, with particular emphasis on recent transcriptomic and single-cell data.

Angiotensin II: Biochemical Profile and Experimental Utility

Angiotensin II is an endogenous octapeptide best known for its role in the renin-angiotensin system. Its primary actions include vasoconstriction, aldosterone secretion, and regulation of renal sodium and water reabsorption. Mechanistically, Angiotensin II activates G protein-coupled receptors (principally AGTR1 and AGTR2) on vascular smooth muscle cells, triggering phospholipase C activation, IP3-dependent calcium release, and downstream protein kinase C signaling cascades. These molecular events potentiate smooth muscle contraction, hypertrophy, and extracellular matrix remodeling—hallmarks of hypertension and vascular disease.

For experimental applications, Angiotensin II is highly soluble in DMSO (≥234.6 mg/mL) and water (≥76.6 mg/mL), but insoluble in ethanol. Researchers typically prepare stock solutions in sterile water at concentrations above 10 mM, with storage at -80°C preserving peptide integrity for several months. In vitro, 100 nM Angiotensin II administered to VSMCs for 4 hours increases NADH and NADPH oxidase activity, modeling oxidative stress. In vivo, chronic infusion in C57BL/6J (apoE–/–) mice at 500–1000 ng/min/kg via subcutaneous minipumps robustly induces AAA, characterized by medial thickening, adventitial disruption, and inflammatory infiltration. These features make Angiotensin II indispensable for hypertension mechanism study, cardiovascular remodeling investigation, and abdominal aortic aneurysm modeling.

Intersections of Angiotensin II Signaling and Cellular Senescence in AAA

While Angiotensin II-induced vascular injury has been a cornerstone of AAA research, recent findings highlight a pivotal role for cellular senescence and its secretory phenotype in AAA pathogenesis (Zhang et al., 2025). Single-cell RNA sequencing and machine learning analyses have identified senescence-related genes (SRGs) such as ETS1 and ITPR3 as upregulated in both human AAA samples and Angiotensin II-infused mouse models. Notably, ITPR3 encodes the type 3 inositol 1,4,5-trisphosphate receptor, directly linking Angiotensin II-mediated phospholipase C activation and IP3-dependent calcium release to senescent cell phenotypes.

The study by Zhang and colleagues demonstrated that senescent endothelial cells, characterized by elevated ETS1 and ITPR3 expression, accumulate in the aortic wall during AAA progression. Their data suggest that Angiotensin II not only drives VSMC hypertrophy and inflammation but also accelerates endothelial senescence, thereby amplifying matrix degradation and vascular instability. This mechanistic insight extends the classical paradigm of Angiotensin II from being solely a hypertensive and remodeling agent to a key modulator of vascular aging and senescence-associated secretory phenotype (SASP).

Molecular Pathways: From Angiotensin Receptor Signaling to Senescent Phenotype

Angiotensin II acts primarily via the AGTR1 subtype to activate phospholipase C (PLC), generating diacylglycerol (DAG) and inositol trisphosphate (IP3). The resultant IP3 binds to ITPR3 on the endoplasmic reticulum, releasing intracellular calcium and activating calcium-dependent kinases and transcription factors. This axis not only promotes VSMC contraction and hypertrophy but also regulates gene expression profiles associated with senescence—such as increased ETS1 and ITPR3 levels, as highlighted in the recent transcriptomic analysis (Zhang et al., 2025).

Moreover, chronic Angiotensin II exposure upregulates pro-inflammatory cytokines, matrix metalloproteinases (MMPs), and reactive oxygen species (ROS), synergizing with senescent cell accumulation to compromise vascular integrity. This is particularly salient in AAA models, where the convergence of oxidative stress, calcium signaling, and SASP factors promotes adventitial tissue dissection and aneurysmal dilation.

Experimental Design Considerations for Vascular Injury and AAA Modeling

Given the multifaceted mechanisms of Angiotensin II, experimental protocols must account for species, strain, infusion rate, and duration. For example, C57BL/6J (apoE–/–) mice are highly susceptible to AAA induction with subcutaneous Angiotensin II at 500–1000 ng/min/kg for 4 weeks. Tissue-specific outcomes can be modulated by co-treatment with aldosterone, mineralocorticoid receptor antagonists, or senolytic agents to dissect the interplay between hypertensive, remodeling, and senescence pathways.

In vitro studies typically employ 100 nM Angiotensin II to stimulate VSMC hypertrophy, migration, and ROS generation, with endpoints including NADH/NADPH oxidase activity, calcium flux assays, and quantification of SASP-associated cytokines. The solubility profile of Angiotensin II facilitates high-concentration stock preparation, enabling precise dosing and reproducibility in cell-based experiments.

Translational Implications: Biomarker Discovery and Therapeutic Innovation

The identification of senescence-related biomarkers such as ETS1 and ITPR3 in Angiotensin II-induced AAA models has significant translational potential. As demonstrated by Zhang et al. (2025), these markers exhibit robust diagnostic performance in both human serum and murine tissues, offering a noninvasive adjunct to imaging for early AAA detection. Furthermore, interventions targeting senescent cell populations or modulating Angiotensin II/GPCR signaling could attenuate SASP and matrix degradation, representing innovative strategies for AAA therapy beyond conventional blood pressure control.

These insights also inform the use of Angiotensin II in drug screening platforms, enabling the evaluation of candidate molecules that disrupt the senescence-inflammation axis. Such approaches may ultimately refine patient stratification, risk prediction, and therapeutic targeting in vascular disease.

Contrast with Prior Literature and Novel Contributions

Unlike previous reviews that focused on either the general GPCR signaling mechanisms of Angiotensin II or its role in VSMC hypertrophy (see "Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy..."), this article specifically interrogates the mechanistic interface between Angiotensin II-driven molecular signaling and the emergence of cellular senescence signatures in AAA. By integrating recent single-cell and machine learning-derived biomarker data with established Angiotensin II pathophysiology, we provide a framework for leveraging this peptide not only as a hypertensive stimulus but as a tool for dissecting senescence-associated vascular remodeling. This synthesis offers actionable guidance for designing experiments that bridge molecular signaling, senescence biology, and translational biomarker discovery, extending the scope of current research in vascular injury and AAA.

Conclusion

Angiotensin II remains a cornerstone for modeling hypertension, vascular remodeling, and AAA in experimental systems. New evidence linking its signaling pathways—specifically phospholipase C activation, IP3-dependent calcium release, and aldosterone secretion—with cellular senescence and biomarker expression (ETS1, ITPR3) opens avenues for both mechanistic insight and translational innovation. By bridging hypertensive, remodeling, and senescence paradigms, Angiotensin II enables a comprehensive approach to cardiovascular disease research and therapeutic development.